北京大学学报（医学版） ›› 2022, Vol. 54 ›› Issue (5): 810-813. doi: 10.19723/j.issn.1671-167X.2022.05.005
肿瘤早期预警生物标志物的研究与思考
柯杨*(
),王敏敏,刘萌飞,刘芳芳,刘英,何忠虎*()
- 北京大学肿瘤医院暨北京市肿瘤防治研究所遗传学研究室，恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
杨 柯*(),敏敏 王,萌飞 刘,芳芳 刘,英 刘,忠虎 何*()
中图分类号:
- R73-3
| 1 |
Arya SK , Bhansali S . Lung cancer and its early detection using biomarker-based biosensors[J]. Chem Rev, 2011, 111 (11): 6783- 6809.
doi: 10.1021/cr100420s |
| 2 |
Li W , Li C , Zhou T , et al. Role of exosomal proteins in cancer diagnosis[J]. Mol Cancer, 2017, 16 (1): 145.
doi: 10.1186/s12943-017-0706-8 |
| 3 |
Seijo LM , Peled N , Ajona D , et al. Biomarkers in lung cancer screening: achievements, promises, and challenges[J]. J Thorac Oncol, 2019, 14 (3): 343- 357.
doi: 10.1016/j.jtho.2018.11.023 |
| 4 |
Li L , Choi JY , Lee KM , et al. DNA methylation in peripheral blood: A potential biomarker for cancer molecular epidemiology[J]. J Epidemiol, 2012, 22 (5): 384- 394.
doi: 10.2188/jea.JE20120003 |
| 5 |
Anindo MI , Yaqinuddin A . Insights into the potential use of microRNAs as biomarker in cancer[J]. Int J Surg, 2012, 10 (9): 443- 449.
doi: 10.1016/j.ijsu.2012.08.006 |
| 6 |
Issaq HJ , Fox SD , Chan KC , et al. Global proteomics and metabolomics in cancer biomarker discovery[J]. J Sep Sci, 2011, 34 (24): 3484- 3492.
doi: 10.1002/jssc.201100528 |
| 7 |
Goto M , Liu M . Chemokines and their receptors as biomarkers in esophageal cancer[J]. Esophagus, 2020, 17 (2): 113- 121.
doi: 10.1007/s10388-019-00706-8 |
| 8 |
Yazbeck R , Jaenisch SE , Watson DI . From blood to breath: New horizons for esophageal cancer biomarkers[J]. World J Gastroenterol, 2016, 22 (46): 10077- 10083.
doi: 10.3748/wjg.v22.i46.10077 |
| 9 |
Sharma P , Sharma R . miRNA-mRNA crosstalk in esophageal cancer: From diagnosis to therapy[J]. Crit Rev Oncol Hematol, 2015, 96 (3): 449- 462.
doi: 10.1016/j.critrevonc.2015.07.002 |
| 10 |
Hayes DF . Defining clinical utility of tumor biomarker tests: A clinician's viewpoint[J]. J Clin Oncol, 2021, 39 (3): 238- 248.
doi: 10.1200/JCO.20.01572 |
| 11 |
Oon SF , Pennington SR , Fitzpatrick JM , et al. Biomarker research in prostate cancer: Towards utility, not futility[J]. Nat Rev Urol, 2011, 8 (3): 131- 138.
doi: 10.1038/nrurol.2011.11 |
| 12 |
Kern SE . Why your new cancer biomarker may never work: Recurrent patterns and remarkable diversity in biomarker failures[J]. Cancer Res, 2012, 72 (23): 6097- 6101.
doi: 10.1158/0008-5472.CAN-12-3232 |
| 13 | Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: Why, and what can be done to address the problem[J/OL]. BMC Med, 2012, 10: 87(2012-08-09)[2022-06-01]. https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-10-87. |
| 14 |
He Z , Liu Z , Liu M , et al. Efficacy of endoscopic screening for esophageal cancer in China (ESECC): Design and preliminary results of a population-based randomised controlled trial[J]. Gut, 2019, 68 (2): 198- 206.
doi: 10.1136/gutjnl-2017-315520 |
| 15 |
Liu F , Guo F , Zhou Y , et al. The anyang esophageal cancer cohort study: Study design, implementation of fieldwork, and use of computer-aided survey system[J]. PLoS One, 2012, 7 (2): e31602.
doi: 10.1371/journal.pone.0031602 |
| 16 | Wang M, Liu F, Pan Y, et al. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk[J/OL]. Ebiomedicine, 2021, 73: 103674[2022-06-01]. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00468-0/fulltext. |
| 17 | Liu M, Liu Y, Zhou R, et al. Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions[J/OL]. J Pathol, 2022(2022-05-25)[2022-06-01]. https://onlinelibrary.wiley.com/doi/10.1002/path.5970. |
| 18 |
Liu F , Liu M , Liu Y , et al. Oral microbiome and risk of malignant esophageal lesions in a high-risk area of China: A nested case-control study[J]. Chin J Cancer Res, 2020, 32 (6): 742- 754.
doi: 10.21147/j.issn.1000-9604.2020.06.07 |
| 19 |
Zeng H , Ran X , An L , et al. Disparities in stage at diagnosis for five common cancers in China: A multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6 (12): e877- e887.
doi: 10.1016/S2468-2667(21)00157-2 |
| 20 | Chen H, Knebel P, Brenner H. Empirical evaluation demonstrated importance of validating biomarkers for early detection of cancer in screening settings to limit the number of false-positive findings[J/OL]. J Clin Epidemiol, 2016, 75: 108-114[2022-06-01]. https://www.jclinepi.com/article/S0895-4356(16)00059-7/fulltext. |
| [1] | 张云静,乔丽颖,祁萌,严颖,亢伟伟,刘国臻,王明远,席云峰,王胜锋. 乳腺癌患者新发心血管疾病预测模型的建立与验证：基于内蒙古区域医疗数据[J]. 北京大学学报（医学版）, 2023, 55(3): 471-479. |
| [2] | 曹芳,钟明,刘从容. 宫体POLE突变型内膜样癌合并HPV感染相关性宫颈腺癌1例报道及文献回顾[J]. 北京大学学报（医学版）, 2023, 55(2): 370-374. |
| [3] | 梁丽,李鑫,农琳,董颖,张继新,李东,李挺. 子宫内膜癌微卫星不稳定性分析: 微小微卫星变换的意义[J]. 北京大学学报（医学版）, 2023, 55(2): 254-261. |
| [4] | 张波. 弥漫性神经内分泌细胞肿瘤病理学：共性与异质性[J]. 北京大学学报（医学版）, 2023, 55(2): 210-216. |
| [5] | 马芮,宣岩,段瑶,帅婷. 口腔颌面部恶性肿瘤患者术后正念水平调查及影响因素分析[J]. 北京大学学报（医学版）, 2022, 54(4): 727-734. |
| [6] | 蔡天玉,朱振鹏,徐纯如,吉星,吕同德,郭振可,林健. 成纤维细胞生长因子受体2在肾透明细胞癌中的表达及意义[J]. 北京大学学报（医学版）, 2022, 54(4): 628-635. |
| [7] | 陈怀安,刘硕,李秀君,王哲,张潮,李凤岐,苗文隆. 炎症生物标志物对输尿管尿路上皮癌患者预后预测的临床价值[J]. 北京大学学报（医学版）, 2021, 53(2): 302-307. |
| [8] | 唐迅,张杜丹,刘晓非,刘秋萍,曹洋,李娜,黄少平,窦会东,高培,胡永华. China-PAR脑卒中模型在北方农村人群中预测脑卒中发病风险的应用[J]. 北京大学学报（医学版）, 2020, 52(3): 444-450. |
| [9] | 杨飞龙,洪锴,赵国江,刘承,宋一萌,马潞林. 基于长链非编码RNA的生物信息学分析构建膀胱癌预后模型并确定预后生物标志物[J]. 北京大学学报（医学版）, 2019, 51(4): 615-622. |
| [10] | 唐雯,高峻逸,马辛宇,张超贺,马连韬,王亚沙. 循环神经网络模型在腹膜透析临床预后预测中的初步应用[J]. 北京大学学报（医学版）, 2019, 51(3): 602-608. |
| [11] | 王玉华,张国华,张令令,罗俊丽,高兰,赵绵松. 合并恶性肿瘤的类风湿关节炎74例[J]. 北京大学学报（医学版）, 2018, 50(6): 986-990. |
| [12] | 张帆，张树栋，肖春雷，黄毅，马潞林. 80岁及以上前列腺癌患者行腹腔镜前列腺根治性切除术围手术期参数及预后[J]. 北京大学学报(医学版), 2018, 50(5): 822-827. |
| [13] | 蔺轲，谢俊卿，胡永华，孔桂兰. 支持向量机在ICU急性肾损伤患者住院死亡风险预测中的应用[J]. 北京大学学报(医学版), 2018, 50(2): 239-244. |
| [14] | 贺大林，徐珊，郭鹏. 外泌体在泌尿系肿瘤精准诊断中的应用[J]. 北京大学学报(医学版), 2017, 49(4): 561-564. |
| [15] | 唐迅，张杜丹，何柳，曹洋，王晋伟，李娜，黄少平，窦会东，高培，胡永华. China-PAR模型在北方农村人群中预测动脉粥样硬化性心血管疾病发病风险的应用[J]. 北京大学学报(医学版), 2017, 49(3): 439-445. |
|
||
